CIK 0001840904
ATAI ATAI Life Sciences N.V.
Insider trading from SEC Form 4. Last filing Aug 18, 2025. Close $7.35 on Sep 11, 2026, +3% from the 52-week low and -1% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
ATAISep 11, 2026 · close 7.35
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ATAI Life Sciences N.V., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Christian Angermayer director, owner buy | $19M 8,675,799 shares | +20% | - | |
| 45Moderate | Christian Angermayer director, owner buy | $2.5M 1,800,000 shares | +4% | - | |
| 35Weak | Glenn Frank Short Chief Scientific Officer sell | $18k 13,161 shares | -24% | - | |
| 48Moderate | Anne Nagengast Johnson Chief Financial Officer sell | $45k 33,545 shares | -19% | - | |
| 50Moderate | Srinivas Rao See Remarks sell | $102k 75,418 shares | -26% | - | |
| 50Moderate | Kevin James Craig Chief Medical Officer sell | $16k 11,563 shares | -58% | - | |
| 48Moderate | Sahil Kirpekar Chief Business Officer sell | $66k 48,563 shares | -30% | - | |
| 46Moderate | Christian Angermayer director, owner buy | $23M 10,835,718 shares | +36% | - |
Transactions
The last 33 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2025 | Christian Angermayer director, owner | POpen-market purchase Common Sharesindirect: By Apeiron Investment Group Ltd. | +8,675,799 | $2.19 | $19M | 51,045,214 | Aug 18, 2025 |
| Aug 13, 2025 | Srinivas Rao See Remarks | AGrant or award Stock Optionderivative | +650,794 | $0.00 | $0 | 650,794 | Aug 15, 2025 |
| Aug 13, 2025 | Srinivas Rao See Remarks | AGrant or award Stock Optionderivative | +217,777 | $0.00 | $0 | 217,777 | Aug 15, 2025 |
| Jun 26, 2025 | Christian Angermayer director, owner | AGrant or award Stock Optionderivative | +103,000 | $0.00 | $0 | 103,000 | Jun 27, 2025 |
| Jun 26, 2025 | Scott Braunstein director | AGrant or award Stock Optionderivative | +103,000 | $0.00 | $0 | 103,000 | Jun 27, 2025 |
| Jun 26, 2025 | Laurent Fischer director | AGrant or award Stock Optionderivative | +103,000 | $0.00 | $0 | 103,000 | Jun 27, 2025 |
| Jun 26, 2025 | John Francis Hoffman director | AGrant or award Stock Optionderivative | +206,000 | $0.00 | $0 | 206,000 | Jun 27, 2025 |
| Jun 26, 2025 | Sabrina Martucci Johnson director | AGrant or award Stock Optionderivative | +103,000 | $0.00 | $0 | 103,000 | Jun 27, 2025 |
| Jun 26, 2025 | Amir H Kalali director | AGrant or award Stock Optionderivative | +103,000 | $0.00 | $0 | 103,000 | Jun 27, 2025 |
| Jun 26, 2025 | Andrea Heslin Smiley director | AGrant or award Stock Optionderivative | +103,000 | $0.00 | $0 | 103,000 | Jun 27, 2025 |
| Jun 2, 2025 | Christian Angermayer director, owner | AGrant or award Stock Optionderivative | +131,698 | - | - | 131,698 | Jun 4, 2025 |
| Mar 21, 2025 | Sahil Kirpekar Chief Business Officer | SOpen-market sale Common Shares | -48,563 | $1.35 | $66k | 115,636 | Mar 24, 2025 |
| Mar 21, 2025 | Kevin James Craig Chief Medical Officer | SOpen-market sale Common Shares | -11,563 | $1.35 | $16k | 8,437 | Mar 24, 2025 |
| Mar 21, 2025 | Srinivas Rao See Remarks | SOpen-market sale Common Shares | -75,418 | $1.35 | $102k | 212,942 | Mar 24, 2025 |
| Mar 21, 2025 | Glenn Frank Short Chief Scientific Officer | SOpen-market sale Common Shares | -13,161 | $1.35 | $18k | 42,333 | Mar 24, 2025 |
| Mar 24, 2025 | Christian Angermayer director, owner | POpen-market purchase Common Sharesindirect: By Apeiron Investment Group Ltd. | +1,800,000 | $1.40 | $2.5M | 42,369,415 | Mar 24, 2025 |
| Mar 21, 2025 | Anne Nagengast Johnson Chief Financial Officer | SOpen-market sale Common Shares | -33,545 | $1.35 | $45k | 140,045 | Mar 24, 2025 |
| Mar 14, 2025 | Glenn Frank Short Chief Scientific Officer | MOption exercise Common Shares | +32,500 | - | - | 55,494 | Mar 19, 2025 |
| Mar 14, 2025 | Kevin James Craig Chief Medical Officer | MOption exercise Common Shares | +20,000 | - | - | 20,000 | Mar 19, 2025 |
| Mar 14, 2025 | Srinivas Rao See Remarks | MOption exercise Common Shares | +175,000 | - | - | 288,360 | Mar 19, 2025 |
| Mar 14, 2025 | Sahil Kirpekar Chief Business Officer | MOption exercise Common Shares | +100,000 | - | - | 164,199 | Mar 19, 2025 |
| Mar 14, 2025 | Anne Nagengast Johnson Chief Financial Officer | MOption exercise Common Shares | +100,000 | - | - | 173,590 | Mar 19, 2025 |
| Mar 14, 2025 | Sahil Kirpekar Chief Business Officer | MOption exercise Common Sharesderivative | -100,000 | - | - | 0 | Mar 19, 2025 |
| Mar 14, 2025 | Anne Nagengast Johnson Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -100,000 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Mar 14, 2025 | Glenn Frank Short Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -32,500 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Mar 14, 2025 | Kevin James Craig Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -20,000 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Mar 14, 2025 | Srinivas Rao See Remarks | MOption exercise Common Sharesderivative | -175,000 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Mar 3, 2025 | Kevin James Craig Chief Medical Officer | AGrant or award Stock Optionderivative | +757,915 | $0.00 | $0 | 757,915 | Mar 6, 2025 |
| Mar 3, 2025 | Glenn Frank Short Chief Scientific Officer | AGrant or award Stock Optionderivative | +757,915 | $0.00 | $0 | 757,915 | Mar 6, 2025 |
| Mar 3, 2025 | Anne Nagengast Johnson Chief Financial Officer | AGrant or award Stock Optionderivative | +757,915 | $0.00 | $0 | 757,915 | Mar 5, 2025 |
| Feb 14, 2025 | Christian Angermayer director, owner | POpen-market purchase Common Sharesindirect: By Apeiron Investment Group Ltd. | +10,835,718 | $2.10 | $23M | 40,555,215 | Feb 19, 2025 |
| Jan 7, 2025 | Srinivas Rao See Remarks | AGrant or award Stock Optionderivative | +2,340,000 | $0.00 | $0 | 2,340,000 | Jan 10, 2025 |
| Jan 2, 2025 | Gerd Kochendoerfer Chief Operating Officer | AGrant or award Stock Optionderivative | +1,450,000 | $0.00 | $0 | 1,450,000 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Christian Angermayerdirector, owner
- Scott Braunsteinceo, chair, officer, director
- Kevin James CraigChief Medical Officer
- Laurent Fischerceo, president, officer, director
- John Francis Hoffmandirector
- Sabrina Martucci Johnsonofficer, director
- Anne Nagengast JohnsonChief Financial Officer
- Amir H Kalalidirector
- Sahil KirpekarChief Business Officer
- Gerd KochendoerferChief Operating Officer
- Srinivas RaoSee Remarks
- Glenn Frank ShortChief Scientific Officer
- Andrea Heslin Smileydirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.